anti-SARS-CoV-2 ORF7a antibody
ARG43728
ApplicationsELISA, ImmunoHistoChemistry, ImmunoHistoChemistry Paraffin
Product group Antibodies
TargetORF7a
Overview
- SupplierArigo Biolaboratories
- Product Nameanti-SARS-CoV-2 ORF7a antibody
- Delivery Days Customer23
- Application Supplier Note* The dilutions indicate recommended starting dilutions and the optimal dilutions or concentrations should be determined by the scientist.
- ApplicationsELISA, ImmunoHistoChemistry, ImmunoHistoChemistry Paraffin
- CertificationResearch Use Only
- ClonalityPolyclonal
- Concentration1 mg/ml
- ConjugateUnconjugated
- Gene ID43740573
- Target nameORF7a
- Target descriptionORF7a protein
- Target synonymsGU280_gp07, ORF7a protein
- HostRabbit
- IsotypeIgG
- Protein IDP0DTC7
- Protein NameORF7a protein
- Scientific DescriptionCoronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus. The disease is the cause of the 2019-20 coronavirus outbreak. SARS-CoV-2 virus proteins include structural proteins, non-structural proteins and accessory factors. The structure of SARS-CoV-2 consists of the following: a spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. SARS-CoV-2 non-structural protein is ORF1ab that consists of 16 proteins (nsp1-nsp16), while accessory factors include ORF3a, ORF3b, ORF6, ORF7a, ORF7b, ORF8, ORF9b, ORF7a and ORF7a. ORF7a plays a role as antagonist of host tetherin (BST2), disrupting its antiviral effect. It acts by binding to BST2 thereby interfering with its glycosylation. It may suppress small interfering RNA (siRNA) and may bind to host ITGAL, thereby playing a role in attachment or modulation of leukocytes.
- Storage Instruction-20°C
- UNSPSC41116161